Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
NCT00005964
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating aggressive non-Hodgkin's lymphoma. PURPOSE: Randomized phase II trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have previously untreated aggressive stage II, stage III... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/12/2016
Locations: Veterans Affairs Medical Center - Birmingham, Birmingham, Alabama +46 locations
Conditions: Lymphoma
Register for Updates
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00027573
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy followed by donor peripheral stem cell transplantation in treating patients who have metastatic or unresectable kidney cancer.
Gender:
ALL
Ages:
60 years and below
Trial Updated:
07/12/2016
Locations: CCOP - Mayo Clinic Scottsdale Oncology Program, Scottsdale, Arizona +5 locations
Conditions: Kidney Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
NCT00003700
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have untreated acute lymphoblastic leukemia.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
07/01/2016
Locations: Veterans Affairs Medical Center - Birmingham, Birmingham, Alabama +49 locations
Conditions: Leukemia
Register for Updates
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT00028600
Completed
RATIONALE: Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. The donated stem cells may also help destroy any remaining cancer cells (graft-versus-tumor effect). PURPOSE: This phase II trial is studying how well autologous peripheral stem cell transplant followed by donor peripheral stem cell transplant works in treating patients with multiple myeloma.
Gender:
ALL
Ages:
64 years and below
Trial Updated:
07/01/2016
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California +14 locations
Conditions: Multiple Myeloma, Plasma Cell Neoplasm
Register for Updates
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
NCT00002494
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and alternating regimens of chemotherapy in treating patients who have non-Hodgkin's lymphoma or acute lymphocytic leukemia.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
06/30/2016
Locations: University of California San Diego Cancer Center, La Jolla, California +22 locations
Conditions: Leukemia, Lymphoma
Register for Updates
Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma
NCT00002501
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of cyclophosphamide and filgrastim in treating patients with stage IV, relapsed, or refractory low-grade follicular non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/30/2016
Locations: University of Chicago Cancer Research Center, Chicago, Illinois +14 locations
Conditions: Lymphoma
Register for Updates
Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma
NCT00039195
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy, total-body irradiation, and peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE:... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
06/29/2016
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Lymphoma
Register for Updates
Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine
NCT00595127
Completed
The purpose of this research study is to: (1) determine if the combination of low dose total body irradiation, low dose cyclophosphamide and the addition of fludarabine, and a serum to suppress the immune system can allow selected stem cells to take and grow; (2) determine if selected stem cells from the blood or marrow can take and not cause graft-versus-host disease (GvHD), and; (3) evaluate the side effects of the combination of low dose radiation and chemotherapy drugs used for these transpl... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/29/2016
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Fanconi Anemia
Register for Updates
Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin
NCT00635050
Completed
This study will evaluate the rate of pathological complete response (pCR) to the sequential therapy of Doxil, paclitaxel, and cyclophosphamide with concurrent Avastin for patients with locally advanced invasive (T2,T3, Nany, M0) breast carcinoma. Also, the study will evaluate the clinical and subclinical cardiotoxic effect(s) of this regimen, assess how feasible and safe the study is. Survival without any progression of disease will also be calculated. A regimen of chemotherapy will be given to... Read More
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
06/15/2016
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Invasive Breast Cancer
Register for Updates
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
NCT00486668
Unknown
The primary purpose of this study is to determine whether breast cancer tumors respond (as measured by pathologic complete response: the absence of microscopic evidence of invasive tumor cells in the breast) to combined chemotherapy of AC(doxorubicin and cyclophosphamide) followed by paclitaxel plus trastuzumab or lapatinib or both given before surgery to patients with HER2-positive breast cancer. Trastuzumab will also be given to all patients after surgery. The study will also evaluate the toxi... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/03/2016
Locations: MBCCOP, Gulf Coast, Mobile, Alabama +109 locations
Conditions: Invasive Breast Cancer
Register for Updates
Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma
NCT01435499
Completed
The primary objective of this study is to evaluate the safety and feasibility of administering an allogeneic GM-CSF-secreting lethally irradiated whole melanoma cell vaccine ("melanoma GVAX"), alone or in combination with low dose cyclophosphamide (CPM), for the adjuvant treatment of patients with surgically resected stage IIB-IV melanoma. Secondarily, the investigators will assess in vitro correlates of anti-melanoma immunization by melanoma GVAX, including serological and cellular immune respo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2016
Locations: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Melanoma
Register for Updates
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
NCT01468818
Terminated
Background: * The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient with aldesleukin (IL-2) a drug that keeps the white blood cells active. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 200 patients with melanoma. * This study will use chemot... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/19/2016
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Metastatic Melanoma, Skin Cancer
Register for Updates